Orthocell Limited (ASX: $OCC) announces exceptional results from Striate+™ dental implant study

Regenerative medicine company Orthocell Limited (ASX: $OCC) has announced the remarkable outcome of the Striate+TM dental implant post-market clinical study, revealing a 98.6% success rate in dental implant procedures using Orthocell's Striate+ dental membrane for Guided Bone Regeneration (GBR). The study, a key component for re-certification of EU market approval under the new European Medical Device Regulations, aimed to investigate the effect of the Striate+ collagen membrane on patient-related systemic factors, as well as implant and procedure related factors of peri-implant Marginal Bone Level (MBL) following GBR and implant placement.

Professor Giuseppe Luongo's commentary on Striate+TM dental implant study

Professor Giuseppe Luongo, the chief investigator and dental surgeon, expressed, 'Striate+ is a best-in-class dental membrane that facilitates the highest quality bone and tissue repair. Predictable and high-quality bone regeneration is of utmost importance to deliver functional and aesthetically pleasing outcomes for patients. We are delighted to share this compelling real-world data.'

Summary of Orthocell's Striate+TM dental implant study results

The Striate+TM dental implant post-market clinical study demonstrated an exceptional 98.6% success rate in dental implant procedures using Orthocell's Striate+ dental membrane for Guided Bone Regeneration. The study's results, submitted for presentation at the upcoming European Association for Osseintegration annual meeting, are expected to raise the profile of Striate+ with new and existing dental surgeons, aiding in growing product adoption. With an estimated addressable market worth more than US$700 million per annum, Orthocell is already expanding its revenue and is well-positioned for further growth. The compelling real-world evidence from the study solidifies Striate+ as the optimal medical device for all types of guided bone regeneration and dental implant procedures, showcasing Orthocell's commitment to advancing tissue repair and regeneration.